Markets

H.C. Wainwright Stands By Zevra Stock Despite EU Regulatory Setback — What Traders Need to Know

H.C. Wainwright has reiterated its rating on Zevra Therapeutics despite a significant European regulatory setback, signalling analyst conviction that the market may be overreacting. Here is the full breakdown for active traders.